Sunshine Biopharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.03-31

Sunshine Biopharma (NASDAQ:SBFM) Full Year 2023 Results Key Financial Results Revenue: US$24.1m (up 454% from FY 2022). Net loss: US$4.51m (loss narrowed by 83% from FY 2022). US$0.18 loss per share ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2423210432?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","is_english":true,"pubTime":"2024-03-31 20:49","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2423210432","market":"us","top_or_hot":-1,"title":"Sunshine Biopharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags","media":"Simply Wall St.","content":"<div>\n<p>Sunshine Biopharma (NASDAQ:SBFM) Full Year 2023 Results\nKey Financial Results\n\nRevenue: US$24.1m (up 454% from FY 2022).\nNet loss: US$4.51m (loss narrowed by 83% from FY 2022).\nUS$0.18 loss per share ...</p>\n\n<a href=\"https://finance.yahoo.com/news/sunshine-biopharma-full-2023-earnings-124926560.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sunshine Biopharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSunshine Biopharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-31 20:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/sunshine-biopharma-full-2023-earnings-124926560.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sunshine Biopharma (NASDAQ:SBFM) Full Year 2023 Results\nKey Financial Results\n\nRevenue: US$24.1m (up 454% from FY 2022).\nNet loss: US$4.51m (loss narrowed by 83% from FY 2022).\nUS$0.18 loss per share ...</p>\n\n<a href=\"https://finance.yahoo.com/news/sunshine-biopharma-full-2023-earnings-124926560.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SBFMW","symbol_name":"Sunshine Biopharma Equity Warrant Warrant","start_time":0,"source_url":"https://finance.yahoo.com/news/sunshine-biopharma-full-2023-earnings-124926560.html","article_id":"2423210432","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2423210432","pubTimestamp":1711889366,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"NasdaqCM:SBFM Earnings and Revenue History March 31st 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 7.0%. Earnings per share  missed analyst estimates by 19%.Looking ahead, revenue is forecast to grow 68% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in the US.The company's shares are up 2.5% from a week ago.Every company has them, and we've spotted   3 warning signs for Sunshine Biopharma   you should know about.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SBFMW":"Sunshine Biopharma Equity Warrant Warrant","SBFM":"Sunshine Biopharma Inc."},"translate_title":"阳光生物制药2023年全年收益：收入超出预期，每股收益落后","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SBFM":0.9,"SBFMW":0.9},"content_text":"Sunshine Biopharma (NASDAQ:SBFM) Full Year 2023 Results\nKey Financial Results\n\nRevenue: US$24.1m (up 454% from FY 2022).\nNet loss: US$4.51m (loss narrowed by 83% from FY 2022).\nUS$0.18 loss per share (improved from US$1.76 loss in FY 2022).\n\n\n\n\n  NasdaqCM:SBFM Earnings and Revenue History March 31st 2024\n \n\nAll figures shown in the chart above are for the trailing 12 month (TTM) period\nSunshine Biopharma Revenues Beat Expectations, EPS Falls Short\n Revenue exceeded analyst estimates by 7.0%. Earnings per share (EPS) missed analyst estimates by 19%. \n Looking ahead, revenue is forecast to grow 68% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in the US. \nPerformance of the American Biotechs industry.\n The company's shares are up 2.5% from a week ago. \nRisk Analysis\n What about risks? Every company has them, and we've spotted   3 warning signs for Sunshine Biopharma   you should know about. \nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2423210432"}